Disrupting Prescription Drug Pricing: Mark Cuba...

By João L. Carapinha

February 13, 2026

Exposing Prescription Drug Pricing Flaws Prescription drug pricing in the US is riddled with inefficiencies, as revealed in this
Launch of TrumpRx Drug Pricing: Savings on Essential Medications
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
NHS Cost-Effectiveness Thresholds Boost Drug Approvals and Innovation
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Biomanufacturing Excellence Act: Strengthening U.S. Biopharmaceutical Manufac...
Medicare Drug Price Negotiations: Major Savings for Seniors on Cancer and Chr...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...